Two Unusual Potential Sources of Funding for Longevity Research
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chapter 6: Old People Are People Too, So Let's Act
Career Planning & Adult Development JOURNAL Volume 31, Number 2 ISSN 0736-1920 Summer 2015 OUR FUTURE: Projections of Work and Life Helen Harkness, Guest Editor QThe Future Q The End of Work as We Know It QJobs and Careers on the Front Line of the Future QSilicon Valley and the New Rules of Work Q Training Challenges Facing Education and Training and Career Development in the Future QOld people are people too, so let’s act accordingly Q Crisis of Human Capital in Aerospace: It’s All About the STEM QCollege for All – Reality or Flawed Myth? QOur Jobs: The American Workforce and Economy in Crisis Q The Future Has Arrived: The Future is Now the Present Summer 2015..............................Career Planning and Adult Development JOURNAL..............................1 CAREER PLANNING and ADULT DEVELOPMENT JOURNAL Volume 31, Number 2 ISSN 0736-1920 Summer 2015 OUR FUTURE: Projections of Work and Life Looking Ahead with the Journal,E\Steven E. Beasley, Managing Editor4 Introduction to this Issue, E\ Helen Harkness, PhD, Guest Editor5 Chapter 1: 7KH)XWXUHE\ Leigh Ellen Key8 Chapter 2: 7KH(QGRI:RUNDV:H.QRZ,Wby Andy Hines10 Chapter 3: -REVDQG&DUHHUVRQWKH)URQW/LQHRIWKH)XWXUHby Gary Marx20 Chapter 4: 6LOLFRQ9DOOH\DQGWKH1HZ5XOHVRI:RUNE\Gary A. Bolles28 Chapter 5: 7UDLQLQJ&KDOOHQJHV)DFLQJ(GXFDWLRQDQG7UDLQLQJ DQG&DUHHU'HYHORSPHQWLQWKH)XWXUHE\Timothy C. Mack40 Chapter 6: 2OGSHRSOHDUHSHRSOHWRRVROHW·VDFWDFFRUGLQJO\by Aubrey de Grey47 Chapter 7: &ULVLVRI+XPDQ&DSLWDOLQ$HURVSDFH,W·V$OO$ERXWWKH67(0 by Deborah Westphal51 Chapter 8: &ROOHJHIRU$OO²5HDOLW\RU)ODZHG0\WK"E\ -
Vascular Tissue Challenge Official Rules Updated 2019-08-14
Vascular Tissue Challenge Official Rules Updated 2019-08-14 SECTION 1: Executive Summary 2 SECTION 2: Definitions & Assumptions 3 SECTION 3: Evaluation Criteria 3 SECTION 4: Safety & Care 5 SECTION 5: Registration Requirements 5 SECTION 6: Judging 6 SECTION 7: Timeline 8 SECTION 8: Eligibility, Disqualification, & Appeal 9 SECTION 9: Awards 10 The Methuselah Foundation Vascular Tissue Challenge Rules Page 1 SECTION 1: EXECUTIVE SUMMARY Objectives Summary The Vascular Tissue Challenge (hereafter “Challenge”) is a $500,000 prize purse to be divided among the first three teams who can successfully create thick, human vascularized organ tissue in an in-vitro environment while maintaining metabolic functionality similar to their in vivo native cells throughout a 30 calendar day survival period. NASA’s objective for this Challenge is to produce technologies capable of creating viable thick (>1cm) metabolic tissues that can be used to advance research on human physiology, fundamental space biology, and medicine taking place both on the Earth and the ISS National Laboratory. Specifically, technology innovations may enable the growth of de novo tissues and organs on orbit which may address the risks related to traumatic bodily injury, improve general crew health, and enhance crew performance on future, long-duration missions. Evaluation Criteria Summary Produce an in vitro vascularized tissue that is > 1 centimeter in thickness in all dimensions at the launch of the trial and maintains >85% survival of the required parenchymal cells throughout a 30 calendar day period. Tissues must provide adequate blood perfusion without uncontrolled leakage into the bulk tissue to maintain metabolic functionality similar to their in vivo native cells. -
From Here to Immortality: Anti-Aging Medicine
FromFrom HereHere toto Immortality:Immortaalitty: AAnti-AgingAnnntti-AAgging MMedicineedicine Anti-aging medicine is a $5 billion industry. Despite its critics, researchers are discovering that inter ventions designed to turn back time may prove to be more science than fiction. By Trudie Mitschang 14 BioSupply Trends Quarterly • October 2013 he symptoms are disturbing. Weight gain, muscle Shifting Attitudes Fuel a Booming Industry aches, fatigue and joint stiffness. Some experience The notion that aging requires treatment is based on a belief Thear ing loss and diminished eyesight. In time, both that becoming old is both undesirable and unattractive. In the memory and libido will lapse, while sagging skin and inconti - last several decades, aging has become synonymous with nence may also become problematic. It is a malady that begins dete rioration, while youth is increasingly revered and in one’s late 40 s, and currently 100 percent of baby boomers admired. Anti-aging medicine is a relatively new but thriving suffer from it. No one is immune and left untreated ; it always field driven by a baby- boomer generation fighting to preserve leads to death. A frightening new disease, virus or plague? No , its “forever young” façade. According to the market research it’s simply a fact of life , and it’s called aging. firm Global Industry Analysts, the boomer-fueled consumer The mythical fountain of youth has long been the subject of base will push the U.S. market for anti-aging products from folklore, and although it is both natural and inevitable, human about $80 billion now to more than $114 billion by 2015. -
SENS-Research-Foundation-2019
by the year 2050, cardiovascular an estimated 25-30 the american 85 percent of adults disease years and older age 85 or older remains the most population will suffer from common cause of 2 1 2 dementia. death in older adults. triple. THE CLOCK IS TICKING. By 2030, annual direct The estimated cost of medical costs associated dementia worldwide was 62% of Americans with cardiovascular $818 billion diseases in the united over age 65 have in 2015 and is states are expected to more than one expected to grow to rise to more than chronic condition.1 3 $2 trillion $818 billion. by 2030.1 References: (1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732407/, (2) https://www.who.int/ageing/publications/global_health.pdf, (3) https://www.cdcfoundation.org/pr/2015/heart-disease-and-stroke-cost-america-nearly-1-billion-day-medical-costs-lost-productivity sens research foundation board of directors Barbara Logan Kevin Perrott Bill Liao Chairperson Treasurer Secretary Michael Boocher Kevin Dewalt James O’Neill Jonathan Cain Michael Kope Frank Schuler 02 CONTENTS 2019 Annual Report 04 Letter From The CEO 06 Outreach & Fundraising 08 Finances 09 Donors erin ashford photography 14 Education 26 Investments 20 Conferences & Events 30 Research Advisory Board 23 Speaking Engagements 31 10 Years Of Research 24 Alliance 32 MitoSENS 34 LysoSENS 35 Extramural Research 38 Publications 39 Ways to Donate cover Photo (c) Mikhail Leonov - stock.adobe.com special 10th anniversary edition 03 FROM THE CEO It’s early 2009, and it’s very late at night. Aubrey, Jeff, Sarah, Kevin, and Mike are sitting around a large table covered in papers and half-empty food containers. -
1 of 16 SAA8-2032718 NONREIMBURSABLE SPACE ACT AGREEMENT BETWEEN the NATIONAL AERONAUTICS and SPACE ADMINISTRATION GEORGE
NONREIMBURSABLE SPACE ACT AGREEMENT BETWEEN THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION GEORGE C. MARSHALL SPACE FLIGHT CENTER AND METHUSELAH FOUNDATION FOR THE CENTENNIAL CHALLENGES LUNAR NUTRITION CHALLENGE ARTICLE 1. AUTHORITY AND PARTIES In accordance with the National Aeronautics and Space Act (51 U.S.C. § 20113(e)), this Agreement is entered into by the National Aeronautics and Space Administration George C. Marshall Space Flight Center, located at Marshall Space Flight Center, AL 35812 (hereinafter referred to as "NASA" or "NASA MSFC") and Methuselah Foundation located at 8021 Flint Street, Springfield , VA 22153-2438 (hereinafter referred to as "Partner" or "MF"). NASA and Partner may be individually referred to as a "Party" and collectively referred to as the "Parties." ARTICLE 2. PURPOSE This Agreement shall be for the purpose of conducting the Lunar Nutrition Challenge for NASA Centennial Challenges program. This Challenge seeks to identify and foster the development and demonstration of novel technologies and/or approaches for food production for long duration space exploration missions. As part of the initial human presence on the Moon by 2024 and a sustainable human presence on the Moon by 2028, NASA's missions will become longer in duration and require sustainable systems that meet lunar crews' needs. This Challenge is focused on how to provide crew members with: • a viable food system for long duration missions • an approach that meets crew members' daily nutritional needs with limited resources • a palatable diet with limited or no dependency on Earth resupplies; and potentially a • ‘harvest' that provides a variety of food choices For the term of this Agreement, the Challenge will be developed and conducted by MF to foster these novel approaches to food production. -
Alagebrium and Complications of Diabetes Mellitus
Eurasian J Med 2019; 51(3): 285-92 Review Alagebrium and Complications of Diabetes Mellitus Cigdem Toprak , Semra Yigitaslan ABSTRACT Glycation is the process of linking a sugar and free amino groups of proteins. Cross-linking of glycation products to proteins results in the formation of cross-linked proteins that inhibit the normal functioning of the cell. Advanced glycation end products (AGEs) are risk molecules for the cell aging process. These ends products are increasingly synthesized in diabetes and are essentially responsible for diabetic complications. They accumulate in the extracellular matrix and bind to receptors (receptor of AGE [RAGE]) to generate oxidative stress and inflammation. particularly in the cardiovascular system. Treatment methods targeting the AGE system may be of clinical importance in reducing and preventing the complications induced by AGEs in diabetes and old age. The AGE cross-link breaker alagebrium (a thiazolium derivative) is the most studied anti-AGE compound in the clinical field. Phase III clinical studies with alagebrium have been successfully conducted, and this molecule has positive effects on cardiovascular hypertrophy, diabetes, hypertension, vas- cular sclerotic pathologies, and similar processes. However, the mechanism is still not fully understood. The primary mechanism is that alagebrium removes newly formed AGEs by chemically separating α-dicarbonyl carbon–carbon bonds formed in cross-linked structures. However, it is also reported that alagebrium is a methylglyoxal effective inhibitor. It is not yet clear whether alagebrium inhibits copper-catalyzed ascorbic acid oxidation through metal chelation or destruction of the AGEs. It is not known whether alagebrium has a direct association with RAGEs. The safety profile is favorably in humans, and studies have been terminated due to financial insufficiency and inability to license as a drug. -
Read Our New Annual Report
The seeds of a concept. The roots of an idea. The potential of a world free of age-related disease. Photo: Sherry Loeser Photography SENS Research Foundation Board of Directors Barbara Logan, Chair Bill Liao, Secretary Kevin Perrott, Treasurer Michael Boocher Jonathan Cain Kevin Dewalt Michael Kope Jim O’Neill Frank Schüler Sherry Loeser Photography 2 Contents CEO Letter (Jim O’Neill) 4 Finances 5 Donors 6 - 7 Fundraising & Conferences 8 - 9 Around the World with Aubrey de Grey 10 Outreach 11 Founding CEO Tribute & Underdog Pharmaceuticals 12 - 13 Investments 14 Welcome New Team Members 15 Education 16 - 17 Publications & Research Advisory Board 18 Research Summaries 19 - 22 Ways to Donate 23 The SRF Team Front row: Anne Corwin (Engineer/Editor), Amutha Boominathan (MitoSENS Group Lead), Alexandra Stolzing (VP of Research), Aubrey de Grey (Chief Science Officer), Jim O’Neill (CEO), Bhavna Dixit (Research Associate). Center row: Caitlin Lewis (Research Associate), Lisa Fabiny-Kiser (VP of Operations), Gary Abramson (Graphics), Maria Entraigues-Abramson (Global Outreach Coordinator), Jessica Lubke (Administrative Assistant). Back row: Tesfahun Dessale Admasu (Research Fellow), Amit Sharma (ImmunoSENS Group Lead), Michael Rae (Science Writer), Kelly Protzman (Executive Assistant). Not Pictured: Greg Chin (Director, SRF Education), Ben Zealley (Website/Research Assistant/ Deputy Editor) Photo: Sherry Loeser Photography, 2019 3 From the CEO At our 2013 conference at Queens College, Cambridge, I closed my talk by saying, “We should not rest until we make aging an absurdity.” We are now in a very different place. After a lot of patient explanation, publication of scientific results, conferences, and time, our community persuaded enough scientists of the feasibility of the damage repair approach to move SENS and SENS Research Foundation from the fringes of scientific respectability to the vanguard of a mainstream community of scientists developing medical therapies to tackle human aging. -
Advanced Glycation End Products
ition & F tr oo u d N f S o c l i e a n n c r e u s o J Journal of Nutrition & Food Sciences Abate G, et al., J Nutr Food Sci 2015, 5:6 ISSN: 2155-9600 DOI: 10.4172/2155-9600.1000440 Review Artice Open Access Advanced Glycation End Products (AGEs) in Food: Focusing on Mediterranean Pasta Abate G1, Delbarba A2, Marziano M1, Memo M1 and Uberti D1,2* 1Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 2Diadem Ltd, Spin Off of Brescia University, Brescia, Italy. *Corresponding author: Uberti D, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy, Tel: +39-0303717509; E-mail: [email protected] Rec Date: Nov 16, 2015; Acc Date: Nov 26, 2015; Pub Date: Nov 30, 2015 Copyright: © 2015 Abate G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Advanced glycation end products, also known as glycotoxins, are a diverse group of highly oxidant compounds with pathogenic significance in aged-chronic disease, including diabetes, cardiovascular disease and neurodegenerative disease. They are produced physiologically in the body when reducing sugar binds to a free amino acid group of macromolecules. Thus conditions such as hyperglycemia and/or oxidative stress can favor AGE product formation, contributing to ageing processes and the exacerbation of pathological states. Beside endogenous AGEs, dietary AGE intake contributes significantly to the body AGE pool. -
Rui Li Phd Thesis for Hard Bound
Glycation of Extracellular Matrix: A Solid-State NMR Study Rui Li Robinson College and Department of Chemistry University of Cambridge September 2019 This thesis is submitted for the degree of Doctor of Philosophy. Declaration This thesis is the result of my own work and includes nothing which is the outcome of work done in collaboration except as specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution. It does not exceed the prescribed word limit for the Degree Committee. Rui Li September 2019 Glycation of Extracellular Matrix: A Solid-State NMR Study Rui Li The main aim of this thesis is to investigate the glycation products, especially glycation intermediate products, generated in the glycation reaction model in vitro extracellular matrix (ECM) and ribose-5-phosphate using solid-state nuclear magnetic resonance (SSNMR) spectroscopy. The background and motivations of this project are outlined in chapter 1. Chapter 2 reviews the current understanding of the composition and organisation of the ECM, the structure of collagen and the critical roles collagen plays in the ECM. Chapter 3 introduces the glycation reaction and summarises the glycation products identified to date, with a discussion of the most widely-used characterisation techniques and in vitro model systems for studying the glycation reaction and glycation products. -
Skin Advanced Glycation Endproducts (Ages) Glucosepane And
Page 1 of 47 Diabetes Skin Advanced Glycation Endproducts (AGEs) Glucosepane and Methylglyoxal Hydroimidazolone are Independently Associated with Long- term Microvascular Complication Progression of Type I diabetes Saul Genuth1*, Wanjie Sun2, Patricia Cleary2, Xiaoyu Gao2, David R Sell3, John Lachin2, the DCCT/EDIC Research Group, Vincent M. Monnier3,4* Short Title: Collagen AGEs and Microvascular Complications Departments: From the 1Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio; the 2Biostatistics Center, George Washington University, Rockville, Maryland; the 3Departments of Pathology and 4Biochemistry, and Case Western Reserve University School of Medicine, Cleveland, Ohio. *Co-corresponding authors: Vincent Monnier MD, 216-368-6613 [phone]; 216-368-1357[fax], email: [email protected], and Saul Genuth MD, email: [email protected]; 216-368-5032[phone]; 216-844-8900[fax] 1 Diabetes Publish Ahead of Print, published online September 3, 2014 Diabetes Page 2 of 47 Abbreviations: AER, albumin excretion rate; AGE, advanced glycation end product; CML, Nε- (carboxymethyl)-lysine; DCCT, Diabetes Control and Complications Trial; EDIC, Epidemiology of Diabetes Interventions and Complications; GSPNE, glucosepane; CEL, carboxyethyl-lysine; G-H1, glyoxal hydroimidazolone; MG-H1, methylglyoxal hydroimidazolone. EDTRS, Early Treatment of Diabetic Retinopathy Scale; LRT, likelihood ratio test. 2 Page 3 of 47 Diabetes ABSTRACT Six skin collagen AGEs originally measured near Diabetes Control and Complications Trial (DCCT) closeout in 1993 may contribute to the “metabolic memory” phenomenon reported in the follow-up EDIC complications study. We now investigated whether addition of 4 originally unavailable AGEs, i.e. glucosepane (GSPNE), hydroimidazolones of methylglyoxal (MG-H1) and glyoxal (G-H1), and carboxyethyl-lysine (CEL), improves associations with incident retinopathy , nephropathy , and neuropathy events during 13-17 years post DCCT. -
Advanced Glycation End-Products Can Activate Or Block Bitter Taste Receptors
nutrients Article Advanced Glycation End-Products Can Activate or Block Bitter Taste Receptors Appalaraju Jaggupilli 1 , Ryan Howard 1, Rotimi E. Aluko 2 and Prashen Chelikani 1,* 1 Manitoba Chemosensory Biology Research Group, Department of Oral Biology, University of Manitoba, Children’s Hospital Research Institute of Manitoba (CHRIM), Winnipeg, MB R3E 0W4, Canada; [email protected] (A.J.); [email protected] (R.H.) 2 Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; [email protected] * Correspondence: [email protected]; Tel.: +204-789-3539; Fax: +204-789-3913 Received: 22 May 2019; Accepted: 10 June 2019; Published: 12 June 2019 Abstract: Bitter taste receptors (T2Rs) are expressed in several tissues of the body and are involved in a variety of roles apart from bitter taste perception. Advanced glycation end-products (AGEs) are produced by glycation of amino acids in proteins. There are varying sources of AGEs, including dietary food products, as well as endogenous reactions within our body. Whether these AGEs are T2R ligands remains to be characterized. In this study, we selected two AGEs, namely, glyoxal-derived lysine dimer (GOLD) and carboxymethyllysine (CML), based on their predicted interaction with the well-studied T2R4, and its physiochemical properties. Results showed predicted binding affinities (Kd) for GOLD and CML towards T2R4 in the nM and µM range, respectively. Calcium mobilization assays showed that GOLD inhibited quinine activation of T2R4 with IC 10.52 4.7 µM, whilst CML 50 ± was less effective with IC 32.62 9.5 µM. To characterize whether this antagonism was specific 50 ± to quinine activated T2R4 or applicable to other T2Rs, we selected T2R14 and T2R20, which are expressed at significant levels in different human tissues. -
Ÿþc R Y O N I C S M a G a Z I N E , Q 1 2 0
2007 RECAP 1st Quarter 2008 • Volume 29:1 2007 ANnual Review page 5 Member Profile: Wes Du Charme page 3 7th Alcor Conference Recap page 13 Cryonics and Religion: Friends or Foes? page 19 INSIDE CRYONICS 2 From the Editor 1ST QUARTER 2008 • VOLUME 29:1 19 Cryonics and Religion: Friends or Foes? The cryonics community recognizes the importance and challenge of being 1st Quarter 2008 • Volume 29:1 understood by the general 2007 RECAP public. Religion plays a sub- Cover shows opening reception stantial role in our diverse at the 7th Alcor conference. 2007 ANnual society and may seem to Review Photo by Brian Harris. page 5 some to be at odds with many facets of scientific COVER STORY: PAGE 5 advancement. Meet one theologian who feels the 2007 Annual Review: Today, over ultimate success of cryonics 850page people 3 in the world rely on the is contingent upon the sup- Member Profile: Wes Du CharmeAlcor Life Extension Foundation for Recap port of more than just great Conferencecryopreservation page 13 services. Enrich your 7th Alcor scientific minds. understanding of present-day clinical advancements with the potential to CryonicsFriends and Religion: or Foes?page 19 significantly benefit Alcor’s growing 22 Book Review: Ending membership base in years to come. Aging Likened to a good detective novel, Ending Aging allures the reader into a real- life tale of the mysteries of aging. The author, Dr. 3 Member Profile: Wes Du Charme Aubrey de Grey, has been Wes Du Charme – psychologist, author and barber shop quartet the center of controversy singer – celebrates his thirteenth year as an Alcor member in since proposing a systematic June 2008.